- ValiRx said it had generated further positive results from tests of a lung cancer treatment.

Further to the release of pharmacokinetic data from the completed second-phase clinical trial, the company also released data pertaining to disease impact.

"The results demonstrate that the VAL401 treatment has a statistically significant improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment," the company said.

At 9:26am: [LON:VAL] ValiRx PLC share price was +1.13p at 4.25p

Story provided by